{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:22:24Z","timestamp":1770326544431,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.euroneuro.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,4,2]],"date-time":"2017-04-02T00:16:05Z","timestamp":1491092165000},"page":"667-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats"],"prefix":"10.1016","volume":"27","author":[{"given":"P.","family":"Lazzari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Marcello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mastinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.03.010_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.euroneuro.2017.03.010_bib2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13104-015-1172-2","article-title":"Prescribing preferences in rapid tranquillisation: a survey in Belgian psychiatrists and emergency physicians","volume":"5","author":"Bervoets","year":"2015","journal-title":"BMC Res."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00213-010-2124-0","article-title":"AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents","volume":"215","author":"Black","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib4","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1096\/fj.13-247643","article-title":"Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity","volume":"28","author":"Boon","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib6","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1111\/j.1460-9568.2005.04121.x","article-title":"Dopaminergic regulation of orexin neurons","volume":"21","author":"Bubser","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib7","first-page":"6","article-title":"Hypocretin\/orexin regulation of dopamine signaling: implications for reward and reinforcement mechanisms","volume":"21","author":"Calipari","year":"2012","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1098\/rstb.2006.1856","article-title":"Gastrointestinal hormones regulating appetite","volume":"361","author":"Chaudhri","year":"2006","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib9","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JCP.0b013e3181bfe13e","article-title":"30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice","volume":"29","author":"Coccurello","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00213-006-0368-5","article-title":"Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects","volume":"186","author":"Coccurello","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.eurpsy.2015.09.009","article-title":"Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: an 8-week randomised controlled trial","volume":"30","author":"Conus","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.ijo.0802928","article-title":"Antipsychotic drug-induced weight gain: development of an animal model","volume":"29","author":"Cope","year":"2005","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"Deng","year":"2013","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2147\/NDT.S5463","article-title":"Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia","volume":"7","author":"Di Lorenzo","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib17","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/ijo.2009.67","article-title":"The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation","volume":"33","author":"Di Marzo","year":"2009","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/adb.12056","article-title":"The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food","volume":"19","author":"Dore","year":"2014","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib19","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.2337\/db06-0504","article-title":"Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats","volume":"55","author":"Doyon","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0306-4522(02)00017-9","article-title":"Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area","volume":"111","author":"Fadel","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib21","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation","volume":"6","author":"Fern\u00f8","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bmc.2016.01.033","article-title":"Pyrazole antagonists of the CB1 receptor with reduced brain penetration","volume":"24","author":"Fulp","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.euroneuro.2013.11.009","article-title":"A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia","volume":"24","author":"Gil-Ad","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1194\/jlr.M011320","article-title":"Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes","volume":"52","author":"Goto","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbr.2009.09.032","article-title":"Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance","volume":"207","author":"Guesdon","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib26","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1517\/14728222.9.2.267","article-title":"Treating the metabolic syndrome: acetyl-coa carboxylase inhibition","volume":"9","author":"Harwood","year":"2005","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.biopsych.2005.04.008","article-title":"Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?","volume":"58","author":"Hillebrand","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/dom.12447","article-title":"A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis","volume":"17","author":"Hsiao","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib30","doi-asserted-by":"crossref","first-page":"e93310","DOI":"10.1371\/journal.pone.0093310","article-title":"Metformin and berberine prevent olanzapine-induced weight gain in rats","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1749-6632.2002.tb04293.x","article-title":"Leptin signaling, adiposity, and energy balance","volume":"967","author":"J\u00e9quier","year":"2002","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin","volume":"100","author":"Jin","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib33","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/ijms15046184","article-title":"Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease","volume":"15","author":"Jung","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib35","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1073\/pnas.121164498","article-title":"Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance","volume":"98","author":"Kim","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib36","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib37","unstructured":"Lazzari, P., Murineddu, G., Manca, I., Loriga, G., Pinna, G.A., 2012a. Myrtanil substituentin 3 position of pyrazole ring determines CB1 agonism of novel 4,5-dihydrobenzo-oxa-cycloheptapyrazole cannabinoids. In: Research Triangle Park, NC, USA, editor. International Cannabinoid Research Society. Symposium on the Cannabinoids: Proceedings of the 22nd Annual International Cannabinoid Research Society. pp. 3\u201318."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib38","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/187152412803760636","article-title":"Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2\u05f3-yl pyrazole carboxamides","volume":"12","author":"Lazzari","year":"2012","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbr.2010.11.022","article-title":"Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice","volume":"217","author":"Lazzari","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib40","doi-asserted-by":"crossref","first-page":"e104160","DOI":"10.1371\/journal.pone.0104160","article-title":"Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment","volume":"9","author":"Lian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib41","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/oby.2010.17","article-title":"Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625","volume":"18","author":"Liebig","year":"2010","journal-title":"Obesity"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuroscience.2014.12.046","article-title":"Regulation of the mesolimbic dopamine circuit by feeding peptides","volume":"289","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12192-015-0653-5","article-title":"Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes","volume":"21","author":"Lu","year":"2016","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3945\/jn.108.097618","article-title":"Homeostatic and hedonic signals interact in the regulation of food intake","volume":"139","author":"Lutter","year":"2009","journal-title":"J. Nutr."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib45","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1471-4159.2009.06549.x","article-title":"Central and peripheral consequencesof the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant","volume":"112","author":"Mart\u00edn-Garc\u00eda","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbr.2012.06.033","article-title":"NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile","volume":"234","author":"Mastinu","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phrs.2013.06.001","article-title":"NESS06SM reduces body weight with an improved profile relative to SR141716A","volume":"74","author":"Mastinu","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib48","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.metabol.2013.06.011","article-title":"Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats","volume":"62","author":"Merroun","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib49","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/mp.2012.145","article-title":"Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity","volume":"18","author":"Meye","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib51","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/oby.2008.309","article-title":"The CB1 endocannabinoid system modulates adipocyte insulin sensitivity","volume":"16","author":"Motaghedi","year":"2008","journal-title":"Obesity"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib52","first-page":"11","article-title":"\"Schizophrenia past clozapine\": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing","volume":"48","author":"Mustafa","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib53","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1017\/S1092852915000693","article-title":"Mesolimbic dopamine and its neuromodulators in obesity and binge eating","volume":"20","author":"Naef","year":"2015","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib54","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1755-5949.2010.00172.x","article-title":"Neuropsychiatric adverse effects of centrally acting antiobesity drugs","volume":"17","author":"Nathan","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib55","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.2337\/db08-0161","article-title":"Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats","volume":"57","author":"Nogueiras","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib56","first-page":"1","article-title":"A brain on cannabinoids: the role of dopamine release in reward seeking","volume":"8","author":"Oleson","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000204100","article-title":"Induction of NPY\/AgRP orexigenic peptide expression in rat hypothalamus is an early event in fasting: relationship with circulating leptin, insulin and glucose","volume":"23","author":"Palou","year":"2009","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib58","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.pharep.2015.04.014","article-title":"Effects of neuroleptics administration on adult neurogenesis in the rat hypothalamus","volume":"67","author":"Rojczyk","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib59","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.euroneuro.2014.07.001","article-title":"Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST","volume":"24","author":"Rybakowski","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib60","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1523\/JNEUROSCI.5858-09.2010","article-title":"Regulation of nucleus accumbens activity by the hypothalamic neuropeptide melanin-concentrating hormone","volume":"30","author":"Sears","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib61","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/schbul\/sbm141","article-title":"Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review","volume":"34","author":"Sentissi","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole,weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"Skrede","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib63","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/bjp.2008.130","article-title":"The endocannabinoid system in brain reward processes","volume":"154","author":"Solinas","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1017\/S1092852915000784","article-title":"Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital","volume":"21","author":"Stone-Brown","year":"2016","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib65","doi-asserted-by":"crossref","first-page":"E457","DOI":"10.1152\/ajpendo.00489.2013","article-title":"Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity","volume":"306","author":"Tam","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S146114571300093X","article-title":"Modelling olanzapine-induced weight gain in rats","volume":"17","author":"van der Zwaal","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2007.11.078","article-title":"Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution","volume":"585","author":"van der Zwaal","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib68","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1111\/j.1460-9568.2009.06750.x","article-title":"Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716)","volume":"29","author":"Verty","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib69","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.npp.1301142","article-title":"Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis","volume":"32","author":"Vestri","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib70","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1152\/ajpendo.90920.2008","article-title":"Lipoprotein lipase: from gene to obesity","volume":"297","author":"Wang","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib71","doi-asserted-by":"crossref","first-page":"e33548","DOI":"10.1371\/journal.pone.0033548","article-title":"Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain","volume":"7","author":"Weston-Green","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib72","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1017\/S1461145708008560","article-title":"The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain","volume":"11","author":"Weston-Green","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.010_bib73","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.psyneuen.2013.07.010","article-title":"The role of ghrelin signalling in second-generation antipsychotic-induced weight gain","volume":"38","author":"Zhang","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130050834","article-title":"The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors","volume":"141","author":"Zhang","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.03.010_bib75","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/mol.110.064980","article-title":"Genome-wide expression profiling revealed peripheral effects of cannabinoid receptor 1 inverse agonists in improving insulin sensitivity and metabolic parameters","volume":"78","author":"Zhao","year":"2010","journal-title":"Mol. Pharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1730192X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1730192X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T21:56:26Z","timestamp":1535925386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X1730192X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0924977X1730192X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.03.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}